The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”. Federation delegates are this week concluding a visit to Beijing to establish “a better understanding of the numerous healthcare reforms underway in China … and explore closer paths of cooperation in global drug development between China and Europe”.
The EFPIA delegation included global CEOs, EFPIA Director General Richard Bergstrom, and EFPIA President and Sanofi CEO, Chris Viehbacher. The delegates have taken part in a series of events in Beijing, including a conference on Translational Medicine and a workshop on Transparency and Good Governance.
Viehbacher commented: “EFPIA is committed to fostering productive relations with China… The research-based pharmaceutical industry is a global industry, and this visit marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place in China’s life sciences sector.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.